内源性大麻素在胰岛素生产和作用中的作用
内源性大麻素在胰岛素分泌和作用中的作用
Background:
- The endocannabinoid system is involved in different body functions and processes. It helps regulate appetite and mood, and sends signals to the nervous system. It may also be involved in how the body produces insulin during digestion. Researchers want to test two drugs that work on the endocannabinoid system: nabilone and CP-945,598. These drugs may be able to affect insulin levels in the blood. This information may suggest possible new treatments for people with diabetes.
Objectives:
- To study how the endocannabinoid system is involved in insulin production and action.
Eligibility:
- Healthy men between 21 and 55 years of age.
Design:
- Participants will be screened with a physical exam and medical history. They will provide blood and urine samples. They will also have imaging studies to test their brain responses, especially to food-related cues. Some participants will also have a study visit to test their insulin resistance levels.
- Participants will have four separate study visits 6 weeks apart. They will keep a food diary before each visit. At each visit, they will have one of the following combinations of drugs:
- Double placebo
- Placebo and nabilone
- Placebo and low dose of CP-945,598
- Placebo and high dose of CP-945,598.
- Participants will have follow-up visits 1 week after each study visit. Blood samples will be taken....
研究概览
地位
条件
详细说明
Objectives and Specific Aims:
We plan to investigate whether the endocannabinoid system is involved in the regulation of insulin secretion from Beta cells and in the modulation of insulin action in peripheral tissues in humans. We hypothesize that cannabinoid receptor 1 (CB1R) antagonist CP-945,598 will increase insulin secretion from Beta cells and improve insulin sensitivity in peripheral tissues while cannabinoid receptor (CBR) agonist nabilone will decrease insulin secretion from Beta cells and worsen insulin sensitivity in peripheral tissues. Moreover, we will investigate the brain s control over the initial phase of insulin secretion (cephalic insulin response) and the effect of central cannabinoid receptors.
Experimental Design and Methods:
Twenty healthy men, age 21-55, will be recruited for this study. This is a randomized, double-blind, placebo-controlled cross-over study. Each subject will serve as his own control and each person will have four different intervention visits spaced at least 6 weeks apart. During each visit, they will receive one of the following medications in random order: placebo, nabilone 2 mg, CP-945,598 15 mg, or CP-945,598 45 mg. A sequential hyperglycemic-euglycemic clamp procedure and a 3-hr oral glucose tolerance test will be used to study the effect of CP-945,598 and nabilone on insulin secretion and insulin action in healthy men. To identify brain areas involved in cephalic insulin response, a functional MRI will be used to assess brain activation in response to food images in association with frequent blood sampling.
Medical Relevance and Expected Outcome:
Based on our pre-clinical animal data, CB1R antagonist enhances insulin secretion and action in response to glucose while CBR agonist virtually shuts off insulin secretion and worsens insulin action in response to glucose. The application of novel, pre-clinical findings to an understanding of human biology and pathobiology is of fundamental and critical importance. This study will give us a better understanding of the regulators of insulin secretion from Beta cells and insulin sensitivity in humans, and this new understanding is of importance to finding new treatments for type 2 diabetes.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Baltimore、Maryland、美国、21224
- National Institute of Aging, Clinical Research Unit
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
-
INCLUSION CRITERIA:
-
Healthy men only
(We want to study men because the magnitude of acute insulin response for men and women is different. In addition, as women may become pregnant in the course of the study, and since this is a physiology study only, and not one related to treatments, we want to remove any confounders and lessen any chance of drop-out.)
-
Age 21-55 (Age restriction is used to remove age as a confounding factor because Beta cells function tends to deteriorate and first phase secretion becomes less defined with age.
-
Screening laboratory evaluations with no clinically significant abnormal results (minor deviations from normal lab results will be at the discretion of the principal investigator):
- fasting comprehensive metabolic panel
- complete blood count with differential and platelet
- thyroid function test (TSH, free T4)
- urinalysis
- urine drug screen
-
BMI less than 30 (Men with BMI greater than or equal to 30 are excluded because obesity has been associated with altered beta cell function.
-
Have NOT participated in another clinical trial involving any pharmacologic agents within the past 30 days
-
Able to complete an inform consent
-
Agree to not participate in other clinical trials within the study period (at the discretion of the study investigator)
-
EXCLUSION CRITERIA:
-
Women
-
FPG greater than or equal to 100 mg/dl or 2-hr OGTT greater than or equal to 140 mg/dL
-
Evidence of illicit drug use
-
History of substance abuse including marijuana within the past 6 months
-
History of smoking any tobacco products within six months prior to screening
-
Alcohol intake greater than 30 grams (drink more than 2 beers per day OR equivalent amount of alcohol)
-
History of Human Immunodeficiency Virus (HIV) infection
-
History of active or chronic Hepatitis B and/or C infection
-
History of malignancy
-
History of coronary disease
-
History of seizures or other neurologic diseases
-
History of psychiatric illnesses including major depressive disorder, schizophrenia, bipolar disorder
-
Any lifetime history of suicide attempt
-
History of suicidal behavior in the last year
-
Any suicidal behavior during any follow-up visits
-
History of any suicidal ideation of type 4 or 5 on the Columbia-Suicide Severity Rating Scale
(C-SSRS) in the last year
-
Any suicidal ideation of type 4 or 5 on the C-SSRS during any follow-up visits.
-
Patient Health Questionnaire-9 (PHQ-9) score greater than or equal to 10 during screening visit or any follow-up study visits
-
Generalized Anxiety Disorder-7 (GAD-7) score greater than or equal to 10 during screening visit or any follow-up visits
-
History of liver or renal diseases
-
History of gastrointestinal or endocrine disorders
-
History of glucocorticoid use (over one month) or other immunosuppressive agents (any)
-
Any condition or non-removable device contraindicated for MRI (pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments, or history of working as a welders or metal worker)
-
Any medical history that, in the opinion of the investigator(s), will make participation of the subject in the study unsafe
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Changes in insulin sensitivity.
大体时间:CB1R antagonist CP-945,598 will enhance while CR receptor agonist nabilone will suppress first phase insulin response fromB cells in humans
|
This study will give us a better understanding of the regulators of insulin secretion from B cells and insulin sensitivity in humans and this new understanding is of importance to finding new treatments for type 2 diabetes |
CB1R antagonist CP-945,598 will enhance while CR receptor agonist nabilone will suppress first phase insulin response fromB cells in humans
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
胰岛素和其他激素的变化以及大脑对食物图片的反应由大脑的功能性 MRI 证明。
大体时间:90分钟
|
90分钟
|
合作者和调查者
调查人员
- 首席研究员:Chee W Chia, M.D.、National Institute on Aging (NIA)
出版物和有用的链接
一般刊物
- Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia. 2001 Aug;44(8):929-45. doi: 10.1007/s001250100580.
- Straub SG, Sharp GW. Hypothesis: one rate-limiting step controls the magnitude of both phases of glucose-stimulated insulin secretion. Am J Physiol Cell Physiol. 2004 Sep;287(3):C565-71. doi: 10.1152/ajpcell.00079.2004.
- Elahi D, Muller DC, McAloon-Dyke M, Tobin JD, Andres R. The effect of age on insulin response and glucose utilization during four hyperglycemic plateaus. Exp Gerontol. 1993 Jul-Oct;28(4-5):393-409. doi: 10.1016/0531-5565(93)90066-m.
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 999912018
- 12-AG-N018
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The NIA IRP is discussing the plan to make IPD available. A final decision has not been made.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.